

Virus Name: Vinces		Abbreviation: VINV
Status Probable Arbovirus	Select Agent No	SALS Level 2
SALS Basis Placed at this biosafety level based on close antigenic or genetic relationship to other viruses in a group of 3 or more viruses, all of which are classified at this level.		
Other Information		
Antigenic Group Group C		

SECTION I - Full Virus Name and Prototype Number

Prototype Strain Number / Designation 75V-807	Accession Number	Original Date Submitted 9/24/1984
Family Bunyaviridae	Genus Bunyavirus	
Information From Division of Vector-Borne Viral Diseases	Address P.O. Box 2087, Fort Collins, Colorado 80522	
Information Footnote Reviewed by editor		

Section II - Original Source

Isolated By (name) D.B. Francy	Isolated at Institute DVBVD, Fort Collins, CO	
Host Genus Culex (Mel) vomerifer	Species	Host Age/Stage Adult
Sex Female		
<u>Isolated From</u>	<u>Isolation Details</u>	
Signs and Symptoms of Illness	Arthropod Depleted	
Time Held Alive before Inoculation		
Collection Method CDC light trap with CO2	Collection Date 9/24/1974	
Place Collected (Minimum of City, State, Country) Quininde, Ecuador, South America		
Latitude 0° 20' N	Longitude 79° 30' W	
Macrohabitat	Microhabitat	Method of Storage until Inoculated Dry ice and mechanical freezer (-60dC)
Footnotes		

Morphogenesis

Site of Constituent Formation in Cell

Site of Virion Assembly

Site of Virion Accumulation

Inclusion Bodies

Other

Hemagglutination

Hemagglutination

Antigen Source

Erythrocytes (species used)

No

SMB ext. by sucrose-acetone

Goose

pH Range

pH Optimum

5.75-7.0

Temperature Range

Temperature Optimum

4dC, RT

Remarks

Serologic Methods Recommended

CF, PRNT

Footnotes

Section V - Antigenic Relationship and Lack of Relationship to Other Viruses

Antigen of strain 75V-807 was tested by CF with immune mouse ascitic fluids (MIAF) representing viruses of the following serogroups: A, B, C, Bunyamwera, vesicular stomatitis, Capim, Guama, Patois, Simbu, Turlock, Gamboa, Minatitlan, California, and Hart Park. They only reaction was with Group C grouping MIAF. Subsequent tests were performed by serum dilution plaque-reduction neutrali- zation with the following results:

Virus or MIAF	Homologous	75V-807	
		Virus	MIAF
75V-807	1280	1280	1280
Ossa	320	20	320
Gumbo Limbo	160	^a	40
Restan	>5120	320	-
Murutucu	>640	40	-
Madrid	320	-	-
Nepuyo	80	-	-
Apeu	160	40	-
Caraparu	160	40	-
Marituba	320	40	-
Itaqui	>640	-	-
Oriboca	>640	20	-

^a - = <20

Section VI - Biologic Characteristics

Virus Source (all VERTEBRATE isolates)
Blood (LV)

Lab Methods of Virus Recovery (ALL ISOLATIONS)
Newborn mice and primary avian cell cultures

Cell system (a)	Virus passage history (b)	Evidence of Infection							Growth Without CPE +/- (g)
		CPE			PLAQUES				
		Day (c)	Extent (d)	Titer TCD50/ml (e)	Day (c)	Size (f)	Titer PFU/ml (e)		
Duck embryo (PC)	Orig.					No plaques			
Vero (CL)					4		1.7(b)		
Vero (CL)	Vero 1				4		4.9		
Vero (CL)	Vero 4				3		5.3		

(b) Expressed in dex

Section VII - Natural Host Range (Additional text can be added below table)

Vertebrate (species and organ) and arthropod	No. isolations/No. tested	No. with antibody/No. tested Test used	Country and region
Sentinel hamsters *	31		Ecuador
Culex (Mel) vomerifer	2		

* Heart muscle, skeletal muscle, brain, spleen, whole blood

Section VIII - Susceptibility to Experimental Infection (include viremia)

Experimental host and age	Passage history and strain	Inoculation Route-Dose	Evidence of infection	AST (days)	Titer log ₁₀ /ml
Mice (nb)	V1SM1	ic	Death	6	
Mice (nb)		ip	None		
Mice (nb)		sc			
Mice (wn)		ic			
Mice (wn)		V1SM2	ip		

Section IX - Experimental Arthropod Infection and Transmission

Arthropod species & virus source(a)	Method of Infection log ₁₀ /ml (b)		Incubation period (c)		Transmission by bite (d)		Assay of arthropod, log ₁₀ /ml (e)		
	Feeding	Injected	Days	°C	Host	Ratio	Whole	Organ	System

Section X - Histopathology

Character of lesions (specify host)

Inclusion Bodies

Intranuclear

Organs/Tissues Affected

Category of tropism

Section XI - Human Disease

In Nature	Residual	Death
Subclinical	Overt Disease	
Clinical Manifestations		
Number of Cases	Category (i.e. febrile illness, etc.)	

Section XII - Geographic Distribution

Known (Virus detected) Ecuador
Suspected (Antibody only detected)

Section XIII - References

1. Calisher, C.H., et al. 1983. Am. J. Trop. Med. Hyg. 32:877-885.
--

Remarks

--